ACS Nano
·
2025
·
IF 16
Yuan-Hang Wu,Yang Shen,Bing-Feng Wang,Yu-Tong Wang,Shi-Chi Feng,Yi Yu,Yu-Hang Zhang,Zhenhuang Su,Xingyu Gao,Yanqing Li,Jian-Xin Tang
Efforts to improve the performance of perovskite light-emitting diodes (PeLEDs) have predominantly centered on two key strategies: defect passivation and phase modulation, both of which aim to mitigate nonradiative recombination. While recent advances have explored the synergistic mechanisms in multiadditive systems, the inherent multifunctionality of single-additive systems remains underexplored. Here, we investigate a biopharmaceutical agent, ambroxol hydrochloride (AMB), with multifunctional groups as a multifunctional perovskite crystallization regulator. The presence of abundant electron-rich moieties (e.g., −OH and −NH2) facilitates efficient passivation of perovskite grain boundaries via multiple coordination bonds (e.g., O:Pb and N:Pb). These functional groups also exhibit a strong propensity to form hydrogen bonds with halogen ions, thereby effectively suppressing the formation of halogen vacancies and inhibiting ion migration. Furthermore, AMB impedes the adsorption of the spacer molecule phenylethylamine (PEA) on the octahedron surface and competes with PEA for coordination sites, thereby promoting the formation of well-aligned layered phases and enhancing exciton transfer efficiency. Consequently, we obtained spectrally stable sky-blue PeLEDs with a high external quantum efficiency of 22.42%. High-quality active-matrix array displays are further demonstrated, achieving precise independent control of each pixel. These displays exhibit superior brightness and color consistency, making them highly promising for advanced optoelectronic applications.
研究领域:
材料科学
·
光电子学
·
显示技术
✓ 已验证
产品关联
DOI
PubMed
高影响因子
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
·
2023
·
IF 4.9
Dongli Qi,Bei Jia,Hui Peng,Jiachen He,Jiaxin Pi,Pan Guo,Ying Zhang,Xiuping Deng,Jiawei Li,Zhidong Liu
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal lung disease caused by multiple factors. Currently, safe, and effective drugs for the treatment of IPF have been extremely scarce. Baicalin (BA) is used to treat pulmonary fibrosis, IPF, chronic obstructive pulmonary disease, and other lung diseases. Ambroxol hydrochloride (AH), a respiratory tract lubricant and expectorant, is often used to treat chronic respiratory diseases, such as bronchial asthma, emphysema, tuberculosis, and cough. The combination of BA and AH can relieve cough and phlegm, improve lung function, and potentially treat IPF and its symptoms. However, given the extremely low solubility of BA, its bioavailability for oral absorptions is also low. AH, on the other hand, has been associated with certain side effects, such as gastrointestinal tract and acute allergic reactions, which limit its applicability. Therefore, an efficient drug delivery system is urgently needed to address the mentioned problems. This study combined BA and AH as model drugs with L-leucine (L-leu) as the excipient to prepare BA/AH dry powder inhalations (BA/AH DPIs) using the co-spray drying method. We the performed modern pharmaceutical evaluation, which includes particle size, differential scanning calorimetry analysis, X-ray diffraction, scanning electron microscope, hygroscopicity, in vitro aerodynamic analysis, pharmacokinetics, and pharmacodynamics. Notably, BA/AH DPIs were found to be advantageous over BA and AH in treating IPF and had better efficacy in improving lung function than did the positive drug pirfenidone. The BA/AH DPI is a promising preparation for the treatment of IPF given its lung targeting, rapid efficacy, and high lung bioavailability.
研究领域:
药剂学
·
肺病学
·
药物递送系统
·
药理学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）